Strengthening the earnings base through mergers by absorption of group companies
First written in FY2017-Q1. 17 of 18 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2026.
89 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The consolidated subsidiaries ㈱なの花九州, 株式会社永冨調剤薬局, 株式会社鶴丸調剤薬局 and 株式会社白十字総合薬局 carried out a merger by absorption on 1 April 2025, with ㈱なの花九州 as the surviving company.」
A merger by absorption integrating 4 companies in the Kyushu area into なの花九州 was carried out, advancing the integration of group companies. - FY2026-H1AdvancedAnnual report
「The consolidated subsidiaries 株式会社なの花九州, 株式会社永冨調剤薬局, 株式会社鶴丸調剤薬局 and 株式会社白十字総合薬局 carried out a merger by absorption on 1 April 2025, with 株式会社なの花九州 as the surviving company.」
A merger by absorption of 4 companies was carried out on 1 April 2025, with なの花九州 as the surviving company, advancing the integration of group companies. - FY2025AdvancedAnnual report
「The consolidated subsidiaries ㈱なの花東北, ㈱コスモス薬局 and ㈱山形アポテック carried out a merger by absorption on 1 October 2024, with ㈱なの花東北 as the surviving company.」
A merger by absorption of 3 subsidiaries was carried out with なの花東北 as the surviving company, advancing the integration of group companies. - FY2022AdvancedAnnual report
「The consolidated subsidiaries ㈱なの花北海道 and ㈲クリニクス carried out a merger by absorption effective 1 October 2021, with ㈱なの花北海道 as the surviving company.」
After the acquisition of クリニクス, a merger by absorption was carried out, advancing the integration of group companies and the restructuring of the earnings base. - FY2022-Q3AdvancedAnnual report
「The consolidated subsidiary 株式会社なの花北海道 acquired all shares of 有限会社クリニクス effective 1 April 2021 and carried out a merger by absorption effective 1 October 2021, with 株式会社なの花北海道 as the surviving company.」
After acquiring all shares of クリニクス, a merger by absorption was carried out with なの花北海道 as the surviving company, advancing the integration of group companies. - FY2022-Q2AdvancedAnnual report
「The Company and its consolidated subsidiary 株式会社ひまわり看護ステーション carried out a merger by absorption effective 1 July 2021, with the Company as the surviving company.」
ひまわり看護ステーション was merged by absorption into the Company, advancing the integration of group companies. - FY2022-Q1AdvancedAnnual report
「The consolidated subsidiaries 株式会社なの花東日本 and 株式会社メトロファーマシー carried out a merger by absorption effective 1 June 2021, with 株式会社なの花東日本 as the surviving company.」
A merger by absorption of なの花東日本 and メトロファーマシー was carried out, advancing the integration of group companies. - FY2020-Q1AdvancedAnnual report
「The Company and its consolidated subsidiary 株式会社Ａ－システム carried out a merger by absorption effective 1 April 2019, with the Company as the surviving company.」
Effective 1 April 2019, Ａ－システム was merged by absorption into the Company, continuing the integration of group companies. - FY2019AdvancedAnnual report
「The consolidated subsidiaries 株式会社なの花北海道 and 有限会社アリエス薬局 carried out a merger by absorption on 1 March 2019, with 株式会社なの花北海道 as the surviving company.」
Mergers by absorption between subsidiaries were carried out in April 2018, July 2018 and March 2019, continuing the integration of group companies and the restructuring of the earnings base. - FY2019-Q2AdvancedAnnual report
「The consolidated subsidiaries 株式会社アポテック, 株式会社ラパナ, 株式会社メディセーブ and 株式会社コスディック carried out a merger by absorption effective 1 July 2018, with 株式会社アポテック as the surviving company.」
Effective 1 July 2018, a merger by absorption between subsidiaries was carried out, with アポテック as the surviving company, continuing the integration of group companies. - FY2019-Q1AdvancedAnnual report
「The consolidated subsidiaries 株式会社共栄ファーマシー, 有限会社いかるが薬局 and ヘルシートラスト株式会社 carried out a merger by absorption effective 1 April 2018, with 株式会社共栄ファーマシー as the surviving company. The consolidated subsidiaries 株式会社トータル・メディカルサービス and 九州医療食株式会社 carried out a merger by absorption effective 1 April 2018, with 株式会社トータル・メディカルサービス as the surviving company.」
Effective 1 April 2018, 2 mergers by absorption between subsidiaries were carried out. The integration and restructuring of the group's earnings base through the consolidation of group companies is continuing. - FY2018AdvancedAnnual report
「We opened 8 new dispensing pharmacies and acquired 7 companies, representing 19 stores, through share acquisitions, while closing 3 stores and transferring 2 businesses. We also carried out a merger by absorption of 4 group companies to strengthen the earnings base.」
During the consolidated fiscal year under review, 4 group companies were merged by absorption, and the group's earnings base was restructured together with store acquisitions, closures and business transfers. - FY2018-Q3AdvancedAnnual report
「In this business, during the cumulative nine-month period under review, we opened 8 new dispensing pharmacies and acquired 3 companies, representing 5 stores, through share acquisitions, while closing 3 stores and transferring 2 businesses. We also carried out a merger by absorption of 3 group companies to strengthen the earnings base.」
A merger by absorption of 3 group companies was carried out, and the earnings base was restructured together with store acquisitions, closures and business transfers. - FY2018-Q2AdvancedAnnual report
「We also carried out mergers by absorption of 2 group companies to strengthen our earnings base.」
During the cumulative six-month period under review, 2 group companies were merged by absorption, further strengthening the earnings base. - FY2017AdvancedAnnual report
「We also carried out mergers by absorption of 9 group companies to strengthen our earnings base.」
During the consolidated fiscal year under review, 9 group companies were merged by absorption, further strengthening the earnings base. - FY2017-Q3AdvancedAnnual report
「We also carried out mergers by absorption of 5 group companies to strengthen our earnings base.」
During the cumulative nine-month period under review, 5 group companies were merged by absorption, further strengthening the earnings base. - FY2017-Q2AdvancedAnnual report
「We also carried out mergers by absorption of 4 group companies to strengthen our earnings base.」
Following the 2 companies in the first quarter, 4 companies were merged by absorption during the cumulative period under review, strengthening the earnings base. - FY2017-Q1First statedAnnual report
「We also carried out mergers by absorption of 2 group companies to strengthen our earnings base.」
Mergers by absorption of 2 companies were carried out to strengthen the earnings base.